Emerging Immunotherapies for Parkinson Disease

Symptomatic treatment options for Parkinson disease have steadily improved, and individualized therapeutic approaches are becoming established for every stage of the disease. However, disease-modifying therapy with a causal approach is still unavailable. The central causative role of alpha-synuclein...

Descripción completa

Detalles Bibliográficos
Autores principales: Zella, Samis M. A., Metzdorf, Judith, Ciftci, Emine, Ostendorf, Friederike, Muhlack, Siegfried, Gold, Ralf, Tönges, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534677/
https://www.ncbi.nlm.nih.gov/pubmed/30539376
http://dx.doi.org/10.1007/s40120-018-0122-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534677/
https://www.ncbi.nlm.nih.gov/pubmed/30539376
http://dx.doi.org/10.1007/s40120-018-0122-z

Ejemplares similares